Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency Virus-infected individuals
Neuman, M.G., Malkiewicz, I., Phillips, E.J., Rachlis, A.R., Ong, D., Yeung, E. and Shear, N.H. (2002) Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency Virus-infected individuals. Therapeutic Drug Monitoring, 24 (6). pp. 728-736.
*Subscription may be required
Patients infected with the human immunodeficiency virus (HIV) are at higher risk for adverse drug reactions from trimethoprim-sulfamethoxazole (TMP-SMX) than the HIV-negative population. Studying the HIV-positive population the authors aimed to validate the predictive and diagnostic value of the lymphocyte toxicity assay (LTA) for adverse drug reactions. Patient lymphocytes were analyzed for toxicity to SMX and TMP. Of 35 enrolled HIV patients, 18 had TMP-SMX hypersensitivity syndrome reaction (HSR); 10 tolerated the drug; and 5 had never received the drug. When cases with HSR were compared with controls that tolerated the drugs, cytotoxicity was higher for cases: 29.5% ± 10.1% versus 19.3% ± 11.2% for SMX (P < 0.022) and 25.0% ± 11.9% versus 16.3% ± 11.0% for TMP (P < 0.04). The authors' proposed threshold value for assigning positive results for TMP and SMX hypersensitivities was 22.5%. The LTA has a strong potential for use as a diagnostic tool to assess TMP-SMX hypersensitivity in HIV-infected individuals. Larger patient populations, as well as in vitro studies are needed to further address the reasons for elevated results in immunocompromised patients and to validate the usefulness of the test.
|Publication Type:||Journal Article|
|Publisher:||Lippincott Williams & Wilkins|
|Copyright:||© 2002 Lippincott Williams & Wilkins, Inc.|
|Item Control Page|